Mohammed Al-Temimi, MD
Surgical Oncology · San Jose, CANPI 1144562836
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,500 of the $39,229 with a category attached, or 85.4%. Intuitive Surgical accounts for 94.5% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $36,804, more than ten times the $2,033 reported in 2019. Among surgical oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $1032.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$37K
- Histosonics, Inc.$2K
- Johnson & Johnson$232
- Davol Inc.$160
- Myriad Genetic Laboratories, Inc.$126
- AbbVie$22
What the payments were for
- Speaking & faculty fees$33,50085%
- Travel & lodging$4,05710%
- Food & beverage$6722%
- Education$1,0003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 30 | $37,088 |
| Histosonics, Inc. | 2 | $1,602 |
| Johnson & Johnson | 3 | $232 |
| Davol Inc. | 1 | $160 |
| Myriad Genetic Laboratories, Inc. | 1 | $126 |
| AbbVie | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$33,500
- Da Vinci Surgical System$3,408
- Phasix Mesh$160
- Echelon Flex$149
- Harmonic$149
- EVARREST$149
- PROLENE$149
- PreciseTumor$126
How this compares
$39,229 in reported general payments places this provider in the 95th percentile of 209 surgical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $127 |
| Neomycin Sulfate | 12 | $87 |
| Oxycodone Hcl | 18 | $77 |
| Metronidazole | 13 | $41 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in San Jose
- Afshin BahadorSan Diego$701K
- Amir FathiFresno$255K
- Alexander ChristSanta Monica$239K
- Yanghee WooDuarte$131K
- Michael BouvetSan Diego$118K
- Yuman FongDuarte$87K
- Ronald HurstLos Angeles$76K
- Jason Sicklickla Jolla$69K
- Gagandeep SinghDuarte$38K
- Geoffrey KrampitzBurlingame$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.